Literature DB >> 15380603

Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning.

J Keith DeWyngaert1, Marilyn E Noz, Bruce Ellerin, Elissa L Kramer, Gerald Q Maguire, Michael P Zeleznik.   

Abstract

PURPOSE: To demonstrate a method to extract the meaningful biologic information from (111)In-radiolabeled capromab pendetide (ProstaScint) SPECT scans for use in radiation therapy treatment planning by removing that component of the (111)In SPECT images associated with normal structures. METHODS AND MATERIALS: We examined 20 of more than 80 patients who underwent simultaneous (99m)Tc/(111)In SPECT scans, which were subsequently registered to the corresponding CT/MRI scans.A thresholding algorithm was used to identify (99m)Tc uptake associated with blood vessels and CT electron density associated with bone marrow. Corresponding voxels were removed from the (111)In image set.
RESULTS: No single threshold value was found to be associated with the (99m)Tc uptake that corresponded to the blood vessels. Intensity values were normalized to a global maximum and, as such, were dependent upon the quantity of (99m)Tc pooled in the bladder. The reduced ProstaScint volume sets were segmented by use of a thresholding feature of the planning system and superimposed on the CT/MRI scans.
CONCLUSIONS: ProstaScint images are now closer to becoming a biologically and therapeutically useful and accurate image set. After known sources of normal intensity are stripped away, the remaining areas that demonstrate uptake may be segmented and superimposed on the treatment-planning CT/MRI volume.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380603     DOI: 10.1016/j.ijrobp.2004.05.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Fused radioimmunoscintigraphy for treatment planning.

Authors:  Rodney J Ellis; Deborah A Kaminsky
Journal:  Rev Urol       Date:  2006

Review 2.  Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.

Authors:  Gilles Créhange; Chien Peter Chen; Charles C Hsu; Norbert Kased; Fergus V Coakley; John Kurhanewicz; Mack Roach
Journal:  Cancer Treat Rev       Date:  2012-06-15       Impact factor: 12.111

3.  Enhancing the utility of prostascint SPECT scans for patient management.

Authors:  Marilyn E Noz; Grace Chung; Benjamin Y Lee; Gerald Q Maguire; J Keith DeWyngaert; Jay V Doshi; Elissa L Kramer; Antoinette D Murphy-Walcott; Michael P Zeleznik; Noeun G Kwak
Journal:  J Med Syst       Date:  2006-04       Impact factor: 4.460

Review 4.  Prostate-specific membrane antigen-based imaging.

Authors:  Joseph R Osborne; Naveed H Akhtar; Shankar Vallabhajosula; Alok Anand; Kofi Deh; Scott T Tagawa
Journal:  Urol Oncol       Date:  2012-05-31       Impact factor: 3.498

Review 5.  The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients.

Authors:  Ashesh B Jani; Stanley L Liauw; Michael J Blend
Journal:  Clin Med Res       Date:  2007-06

6.  Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.

Authors:  Satyajit Kosuri; Naveed H Akhtar; Michael Smith; Joseph R Osborne; Scott T Tagawa
Journal:  Adv Urol       Date:  2012-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.